Invasive Bladder Carcinoma

Observed

→ investigated in trials for

Cisplatinsmall molecule

17 trials (12 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Mitomycinsmall molecule

15 trials (10 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pembrolizumabmonoclonal antibody

13 trials (10 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Enfortumab Vedotinadc

7 trials (6 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nivolumabmonoclonal antibody

7 trials (5 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Durvalumabmonoclonal antibody

6 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Fluorouracilsmall molecule

5 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Avelumabmonoclonal antibody

4 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Carboplatinsmall molecule

4 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cabozantinibsmall molecule

3 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Methotrexatesmall molecule

3 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nadofaragene Firadenovecgene therapy

3 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Vinblastinesmall molecule

3 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Atezolizumabmonoclonal antibody

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

Invasive Bladder Giant Cell Urothelial Carcinoma

Invasive Bladder Carcinoma studied in …STUDIED_INderived10 of 179show all (up to 200)
→ studied in	NCT03866382Phase 2 · recruiting Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors · condition mapped ONTOLOGY_EXACT · 179 trials mapped (110 active)	—	—	Invasive Bladder Giant Cell Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05987241Phase 2/Phase 3 · recruiting Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study · condition mapped ONTOLOGY_EXACT · 179 trials mapped (110 active)	—	—	Muscle Invasive Bladder Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07061964Phase 2 · recruiting Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial · condition mapped ONTOLOGY_EXACT · 179 trials mapped (110 active)	—	—	Muscle Invasive Bladder Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06770582Phase 2 · recruiting Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial · condition mapped ONTOLOGY_EXACT · 179 trials mapped (110 active)	—	—	Non-Muscle Invasive Bladder Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06833073Phase 2 · recruiting A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) · condition mapped ALIAS · 179 trials mapped (110 active)	—	—	Non-Muscle Invasive Bladder Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06919965Phase 3 · recruiting A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer · condition mapped ALIAS · 179 trials mapped (110 active)	—	—	Non-Muscle Invasive Bladder Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05316155Phase 1/Phase 2 · active not recruiting Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer · condition mapped ALIAS · 179 trials mapped (110 active)	—	—	Non-Muscle Invasive Bladder Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06211764Phase 3 · active not recruiting A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) · condition mapped ALIAS · 179 trials mapped (110 active)	—	—	Non-Muscle Invasive Bladder Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06319820Phase 3 · recruiting A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer · condition mapped ALIAS · 179 trials mapped (110 active)	—	—	Non-Muscle Invasive Bladder Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06877676approved for marketing Pre-Approval Expanded Access Study for TAR-200 Treating Physician Use · condition mapped ALIAS · 179 trials mapped (110 active)	—	—	Non-Muscle Invasive Bladder Carcinoma	1	Observed	clinicaltrials	graph →

Invasive Bladder Carcinoma studied in …STUDIED_INderived10 of 179show all (up to 200)

→ studied in

NCT03866382Phase 2 · recruiting

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors · condition mapped ONTOLOGY_EXACT · 179 trials mapped (110 active)

—

Observed

Muscle Invasive Bladder Urothelial Carcinoma

→ studied in

NCT05987241Phase 2/Phase 3 · recruiting

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study · condition mapped ONTOLOGY_EXACT · 179 trials mapped (110 active)

—

Observed

Muscle Invasive Bladder Urothelial Carcinoma

→ studied in

NCT07061964Phase 2 · recruiting

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial · condition mapped ONTOLOGY_EXACT · 179 trials mapped (110 active)

—

Observed

Non-Muscle Invasive Bladder Urothelial Carcinoma

→ studied in

NCT06770582Phase 2 · recruiting

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial · condition mapped ONTOLOGY_EXACT · 179 trials mapped (110 active)

—

Observed

→ studied in

NCT06833073Phase 2 · recruiting

A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) · condition mapped ALIAS · 179 trials mapped (110 active)

—

Observed

→ studied in

NCT06919965Phase 3 · recruiting

A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer · condition mapped ALIAS · 179 trials mapped (110 active)

—

Observed

→ studied in

NCT05316155Phase 1/Phase 2 · active not recruiting

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer · condition mapped ALIAS · 179 trials mapped (110 active)

—

Observed

→ studied in

NCT06211764Phase 3 · active not recruiting

A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) · condition mapped ALIAS · 179 trials mapped (110 active)

—

Observed

→ studied in

NCT06319820Phase 3 · recruiting

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer · condition mapped ALIAS · 179 trials mapped (110 active)

—

Observed

→ studied in

NCT06877676approved for marketing

Pre-Approval Expanded Access Study for TAR-200 Treating Physician Use · condition mapped ALIAS · 179 trials mapped (110 active)

—

Observed